PCLOF (PharmaCielo) Other Long Term Assets: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PharmaCielo Other Long Term Assets?

PharmaCielo PCLOF +8.77% Other Long Term Assets is $0.00 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

PharmaCielo's other long-term assets for the quarter that ended in Dec. 2025 was $0.00 Mil.

PharmaCielo's quarterly other long-term assets declined from Jun. 2025 ($0.00 Mil) to Sep. 2025 ($-0.00 Mil) but then increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil).

PharmaCielo's annual other long-term assets declined from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($-0.00 Mil) but then increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil).

PharmaCielo Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for PharmaCielo's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCielo Other Long Term Assets Chart

PharmaCielo Annual Data
Trend Aug17 Aug18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long Term Assets
Get a 7-Day Free Trial 0.00 0.00 -0.00 -0.00 -0.00

PharmaCielo Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.00 0.00

PharmaCielo Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $0.00 Mil mean?
PharmaCielo (PCLOF) has a Other Long Term Assets of $0.00 Mil as of Dec. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on PharmaCielo and its competitors.
Is PharmaCielo's Other Long Term Assets too high?
PharmaCielo's current Other Long Term Assets is $0.00 Mil.
How does PharmaCielo's Other Long Term Assets compare to ZTS and UTHR?
PharmaCielo's Other Long Term Assets of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on PharmaCielo and its competitors. PharmaCielo's current Other Long Term Assets is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.04 — trading 55.1% below its estimated fair value. The current Other Long Term Assets is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Other Long Term Assets is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCielo Business Description

Other Exchanges PCLO:Canada
Address 82 Richmond Street East, Suite 805, Toronto, ON, CAN, M5C 1P1
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.